Baxter (BAX) reports Q4 EPS of $0.97, not providing guidance for full-year 2020
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Baxter Reports Fourth-Quarter and Full-Year 2019 Results, Completes Financial Restatement Process
March 17, 2020 7:25 AM EDTFourth-quarter sales of $3.0 billion increased 7% on a reported basis and 9% on an operational basis1 Fourth-quarter GAAP earnings per share (EPS) were a loss of $0.05; adjusted EPS1 totaled $0.97 Full-year sales of $11.4 billion increased 2% on a reported basis and 5% on an operational basis Full-year GAAP EPS were $1.93; adjusted EPS totaled $3.31 With submission of restated financials, company is now current in its SEC reporting obligations
DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX), a leading global medical products company, today announced its complete... More
